Clinical nodal findings and indocyanine green-guided sentinel node mapping in non-metastatic colon cancer: an exploratory prospective cohort stratified by postoperative mismatch-repair status
This exploratory prospective cohort study of 40 non-metastatic colon cancer patients found that while all mismatch-repair-deficient (dMMR) cases exhibited enlarged lymph nodes on CT, this finding failed to distinguish nodal metastasis status, and indocyanine green-guided sentinel node mapping demonstrated only 50% sensitivity, underscoring the need for validation in larger, consecutive cohorts before clinical application.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the fight against colon cancer, knowing exactly how far the disease has spread is the single most important step in deciding a patient's future. When a tumor is found, surgeons remove it along with nearby lymph nodes, the small, bean-shaped filters that act as the body's first line of defense. If cancer cells have escaped the main tumor and settled in these nodes, the disease is considered more advanced, and the treatment plan usually becomes more aggressive. However, spotting these tiny invaders is notoriously difficult. Doctors rely on preoperative scans, like computed tomography, to look for enlarged nodes, but these images are often misleading. A node can swell because of a harmless immune reaction rather than cancer, or it can be small and full of cancer cells yet look perfectly normal. This uncertainty is especially tricky in a specific type of colon cancer driven by a flaw in the body's DNA repair system. These tumors often trigger a strong immune response, causing many nodes to swell without actually containing cancer, making it hard to tell the difference between a false alarm and a real threat.
A team of researchers at the Masaryk Memorial Cancer Institute in the Czech Republic set out to untangle this confusion by looking at two modern tools used to stage this disease. They wanted to see if a specific type of scan could reliably spot the enlarged nodes in patients with this DNA repair flaw, and whether a new technique using a glowing dye could help surgeons find the most critical nodes to test. The study involved forty patients who were scheduled for elective surgery to remove their colon tumors. The researchers did not just look at the final pathology reports; they went back and re-examined the preoperative CT scans with fresh eyes, completely unaware of the final diagnosis or the specific genetic makeup of each tumor. They also tracked the use of indocyanine green, a fluorescent dye injected around the tumor that lights up the lymphatic channels and the first few nodes it drains, allowing surgeons to see them in real-time during the operation.
The results painted a picture of significant complexity rather than a simple solution. When the researchers looked at the CT scans, they found that every single patient with the DNA repair flaw had at least one lymph node that appeared enlarged, measuring five millimeters or more. This happened in all fourteen patients with this specific genetic profile. However, this finding turned out to be a poor guide for determining if cancer was actually present. In this group, the presence of an enlarged node did not distinguish between those who had cancer in their nodes and those who did not. The enlarged nodes were likely a result of the body's intense immune reaction to the tumor rather than the cancer itself. In contrast, patients without this genetic flaw showed enlarged nodes far less often. The study also tested a more complex set of rules for the scans, looking at the shape and texture of the nodes in addition to their size, but this approach still missed nearly half of the patients who actually had cancer in their nodes.
The glowing dye technique, known as sentinel lymph node mapping, worked well at finding the target nodes but struggled to catch the cancer. The dye successfully highlighted a sentinel node in thirty-eight out of the forty procedures, a very high success rate for locating the anatomy. Yet, when the researchers checked if the dye had led them to the cancer, the results were disappointing. Among the twelve patients who were confirmed to have cancer in their lymph nodes and who had a successfully located sentinel node, the dye-guided method only found the cancer in six of them. In the other six cases, the dye led the surgeons to a node that looked clean, while the cancer was hiding in a different node that the dye did not highlight. This means that relying solely on the glowing node to rule out cancer would have missed the disease in half of these cases. The researchers also performed a very detailed, high-powered examination of the sentinel nodes they did find, looking for microscopic traces of cancer that standard tests might miss. While they found tiny clusters of cancer cells in six patients, these were not enough to change the overall staging or the final diagnosis for any of the patients who were initially thought to be cancer-free.
The study concludes that while the glowing dye is excellent at showing surgeons where the lymphatic system is, it is not yet a reliable standalone tool for deciding if cancer has spread in this specific group of patients. Similarly, the common practice of looking for enlarged nodes on a CT scan is not a trustworthy way to diagnose cancer spread in patients with the DNA repair flaw, because the immune system makes so many nodes look suspicious even when they are safe. The researchers emphasize that their findings come from a small, specific group of patients and that the results cannot be applied broadly without further testing. They suggest that before these techniques can be used to change how doctors treat patients, larger studies are needed to understand exactly why the dye misses some cancers and how to better distinguish between harmless swelling and dangerous spread. For now, the standard practice of removing and carefully examining all available lymph nodes remains the most reliable method for ensuring an accurate diagnosis.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.